

ARIC Manuscript Proposal #1930

PC Reviewed: 4/17/12
SC Reviewed: _____

Status: A
Status: _____

Priority: 2
Priority: _____

1.a. Full Title:

Echocardiographic measures of cardiac structure and function and the risk of Atrial Fibrillation in Blacks: the Atherosclerosis Risk in Communities (ARIC) Study.

b. Abbreviated Title (Length 26 characters): Echocardiogram and AF in Blacks

2. Writing Group:

Writing group members: Wobo Bekwelem, Suma Konety, Scott Solomon, Elsayed Soliman, Laura Loehr, Jeffrey R. Misialek, Faye L. Lopez, Ervin R. Fox, Thomas H. Mosley, Alvaro Alonso

I, the first author, confirm that all the coauthors have given their approval for this manuscript proposal. WB [please confirm with your initials electronically or in writing]

First author: Wobo Bekwelem MD, MPH
Address: Department of Internal Medicine
University of Minnesota

Phone: 6126072863 Fax:
E-mail: bekwe001@umn.edu

ARIC author to be contacted if there are questions about the manuscript and the first author does not respond or cannot be located (this must be an ARIC investigator).

Name: **Alvaro Alonso MD, PhD**
Address: Division of Epidemiology and Community Health
University of Minnesota
1300 S 2nd St, Suite 300
Minneapolis, MN 55454
Phone: 612 626 8597
E-mail: alonso@umn.edu

3. Timeline: Following approval of this manuscript by the ARIC Publications Committee this work will lead to manuscript within 6 months (likely by July 2012).

4. Rationale:

Atrial Fibrillation (AF) is the most common cardiac arrhythmia in clinical practice and its prevalence in the population is increasing (1-3). Multiple risk factors have been associated with AF including hypertension, age, and underlying structural and functional cardiac abnormalities such as heart failure, chamber dilatation, diastolic dysfunction, and valvular problems (4-6). Although blacks have a higher prevalence than Caucasians of most AF risk factors (7,8), they are thought to be at lower risk for developing AF (2,11). Echocardiography is a useful modality in evaluating underlying structural and functional heart disease, and several studies have examined the link between various echocardiographic markers of cardiac structure and function, and AF in Caucasians (9,10). To our knowledge, however, no study has examined this association in a large cohort with long term follow up among blacks. Our analyses will be the first to systematically assess echocardiographic parameters predicting AF in blacks, and attempt to identify factors contributing to this disconnect between prevalence of risk factors and AF incidence in this population.

The availability of echocardiograms at visit 3 for members of the Jackson cohort (all black), will allow us to examine, using echocardiography, which measures of cardiac structure and function are associated with development of AF in blacks, what the magnitude and direction of this association is, and how it might explain the possible lower incidence of AF in this population.

5. Main Hypothesis/Study Questions:

We hypothesize that echocardiographic measures of cardiac structure and function are associated independently with incident atrial fibrillation (AF) in Blacks.

As a secondary hypothesis, we propose that addition of ECG measures of increased LA size (p-wave indices) and ECG-LVH (Cornell voltage), to echocardiographic parameters will improve prediction of AF.

6. Design and analysis (study design, inclusion/exclusion, outcome and other variables of interest with specific reference to the time of their collection, summary of data analysis, and any anticipated methodologic limitations or challenges if present).

Design:

This study will assess the association between echocardiographic parameters and the incidence of AF using a longitudinal data analysis approach. Data will be obtained from the visit 3 exam on Blacks in the Jackson cohort who have echocardiographic measures available. For this analysis, we will exclude individuals with prevalent AF at visit 3, and those missing variables in any of the covariates.

Endpoint:

The main outcome variable is time to AF from visit 3 through 2008. Incident AF will be defined by ECGs in visit 4 or ICD9CM code 427.31 or 427.32 in any hospitalization after visit 3 (11,12).

In preliminary analyses, there are approximately 180 new AF events from visit 3 through the end of 2008 among eligible Jackson participants, which will provide adequate power to detect moderate to strong associations.

Exposures:

A. Visit 3 echocardiographic parameters, including the following

1. Left Ventricular systolic Function
 - Ejection Fraction (LVEF) - qualitative
2. Left Ventricular size
 - Left Ventricular Internal Diameter M-Mode (diastole),
3. LV Mass
 - Left Ventricular Mass Index (g/m),
4. Left Atrial size:
 - left atrial diameter (M-mode parasternal long-axis)
5. Transmitral Doppler Velocity Patterns/ LV diastolic function
 - Late inflow Doppler mitral valve velocity time integral (A wave VTI)
 - Early inflow Doppler mitral valve velocity time integral (E wave VTI)

B. Visit 3 ECG parameters, including the following

1. ECG measures of increased LA size (p-wave indices) – yes/no
2. ECG-LVH (Cornell voltage) – yes/no

Main covariates:

We will calculate the individual predicted risk of AF using the recently developed he CHARGE AF risk score, which will be calculated from the following covariates measured at visit 3: Age, height, weight, current smoking, Systolic blood pressure, diastolic blood pressure, anti-hypertensive medications, diabetes, prevalent heart failure, and prevalent myocardial infarction. {Reference: Alonso et al; A simple model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium – submitted}. This predicted risk will be used as an adjustment covariate in all analyses.

Other variables that will be considered as potential confounders include: education, lipids (LDLc, HDLc), sport index, anti-hyperlipidemic medications, digoxin. Incident HF and incident MI will be considered in additional analyses as potential mediators.

Analysis:

We will use Cox proportional hazards with time to AF as the main outcome variable. Echocardiographic parameters will be modeled as a continuous variable and as quintiles. Non-linear associations will be explored with restricted cubic splines. In an initial model, we will adjust for age and sex. A second model will additionally adjust for the CHARGE-AF risk score. A third model will additionally adjust for other potential confounders measured at visit 3, if relevant (see above). In a final model, we will additionally adjust

for incident HF and MI as time-dependent covariates to assess potential mediation. We will determine whether echocardiographic measures improve the predictive ability of the CHARGE AF risk score measuring improvement in C-statistic and calculating the Net Reclassification Improvement.

In a sensitivity analysis, we will exclude cases of AF occurring in the first 2 years after baseline (visit 3), to avoid including possible prevalent AF cases as new incident cases. Interactions between echocardiographic parameters and sex will be examined. We will also examine interactions between these parameters and hypertension (a major risk factor for AF).

Finally, as a secondary analysis, we will compare the predictive ability of ECG measures of increased LA size (p-wave indices) and ECG-LVH (Cornell voltage), with those of echocardiography, and determine whether ECG measures have predictive value beyond that provided by echocardiographic measures.

Limitations:

NT-proBNP, TSH and eGFR, markers of HF, thyroid dysfunction and renal disease respectively, which are recognized risk factors for AF were not measured at visit 3, hence we are unable to adjust for them.

References:

1. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. *Heart*. 2001;86:284-288.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001;285:2370-2375.
3. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. *Am J Cardiol*. 2009;104:1534-1539.
4. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, Oh JK, Leibson C, Montgomery SC, Seward JB. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. *J Am Coll Cardiol*. 2002;40:1636-1644.
5. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. *Arch Intern Med*. 1995;155:469-473.
6. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. *Eur Heart J*. 2006;27:949-953.

7. Sharp A, Tapp R, Francis DP, McG Thom SA, Hughes AD, Stanton AV, Zambanini A, Chaturvedi N, Byrd S, Poulter NR, Sever PS, Mayet J. Ethnicity and left ventricular diastolic function in hypertension: an ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) substudy. *J Am Coll Cardiol.* 2008;52:1015-1021.
8. Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime Risks of Cardiovascular Disease. *N Engl J Med.* 2012;26;366:321-329.
9. Rosenberg MA, Gottdiener JS, Heckbert SR, Mukamal KJ. Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. *Eur Heart J.* 2011;Oct.11.[Epub ahead of print]
10. Jons C, Joergensen RM, Hassager C, Gang UJ, Dixen U, Johannesen A, Olsen NT, Hansen TF, Messier M, Huikuri HV, Thomsen PE. Diastolic dysfunction predicts new-onset atrial fibrillation and cardiovascular events in patients with acute myocardial infarction and depressed left ventricular systolic function: a CARISMA substudy. *Eur J Echocardiogr.* 2010;11:602-607.
11. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ, Folsom AR. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J.* 2009;158(1):111-117.
12. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J.* 2010;159(5):850-856.

7.a. Will the data be used for non-CVD analysis in this manuscript? Yes
 No

b. If Yes, is the author aware that the file ICTDER03 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES_DNA = "CVD Research" would be used?

Yes No

(This file ICTDER03 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? Yes
 No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER03 must be used to exclude those with value RES_DNA = "No use/storage DNA"?

Yes No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this

